Breaking News Instant updates and real-time market news.

NITE

Nightstar Therapeutics

$14.39

-0.47 (-3.16%)

, BOLD

Audentes Therapeutics

$24.30

0.81 (3.45%)

08:35
11/29/18
11/29
08:35
11/29/18
08:35

Barclays to hold a summit

Gene Editing & Gene Therapy Summit will be held in New York on November 29.

NITE

Nightstar Therapeutics

$14.39

-0.47 (-3.16%)

BOLD

Audentes Therapeutics

$24.30

0.81 (3.45%)

QURE

uniQure

$28.64

0.38 (1.34%)

RCKT

Rocket Pharmaceuticals

$16.06

-0.29 (-1.77%)

RGNX

Regenxbio

$63.55

-0.89 (-1.38%)

CLLS

Cellectis

$21.81

0.82 (3.91%)

NTLA

Intellia Therapeutics

$17.09

1.105 (6.91%)

CRSP

Crispr Therapeutics

$37.70

1.34 (3.69%)

  • 29

    Nov

  • 01

    Dec

  • 28

    Nov

NITE Nightstar Therapeutics
$14.39

-0.47 (-3.16%)

10/11/18
10/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sage Therapeutics (SAGE) initiated with an Outperform at Oppenheimer. 2. Herbalife Nutrition (HLF) initiated with a Buy at Jefferies. 3. GreenSky (GSKY) initiated with a Buy at BTIG. 4. Nightstar Therapeutics (NITE) initiated with an Overweight at Cantor Fitzgerald. 5. KLX Energy (KLXE) initiated with a Buy at Gabelli. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/18
CANT
10/11/18
INITIATION
Target $36
CANT
Overweight
Nightstar Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros started Nightstar Therapeutics with an Overweight rating and $36 price target. Nightstar is developing AAV-vector-based gene therapies for ophthalmological indications, Piros tells investors in a research note. The analyst has a positive outlook for Nightstar based on positive data shown in multiple Phase 2 investigator sponsor led trials, a potential first mover advantage, and proof of concept in multiple ocular gene therapy trials.
09/24/18
HCWC
09/24/18
NO CHANGE
Target $8
HCWC
Buy
Nightstar data a de-risking event for Applied Genetic, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis views Nightstar Therapeutics' (NITE) positive preliminary safety and efficacy data originated from its Phase 1/2 trial, which is testing NSR-RPGR for the treatment of X-linked retinitis pigmentosa in patients with the RPGR mutation, as a de-risking event for Applied Genetic's (AGTC) program. The Nightstar data represent "significant validation" for the ongoing Applied Genetic Phase 1/2 trial in XLRP in partnership with Biogen (BIIB), Pantginis tells investors in a research note. He keeps a Buy rating on the shares with an $8 price target.
09/24/18
BMOC
09/24/18
NO CHANGE
Target $41
BMOC
Outperform
Nightstar Therapeutics price target raised to $41 from $30 at BMO Capital
BMO Capital analyst Matthew Luchini raised his price target on Nightstart to $41 and kept his Outperform rating, saying he is adding to his model the impact of NSR-RPGR disclosed last week in the presentation of early dose escalation Phase I/II data. The analyst notes says the improvements in microperimetry cohorts 3-5 "provide preliminary proof-of-concept and support initiation of the expansion study planned for Q4", adding that XLRP could achieve peak sales of about $675M.
BOLD Audentes Therapeutics
$24.30

0.81 (3.45%)

11/26/18
JPMS
11/26/18
INITIATION
Target $35
JPMS
Overweight
Audentes Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Audentes Therapeutics with an Overweight rating and $35 price target. The stock has pulled 40% since early October, which represents an attractive long-term entry point, Rama tells investors in a research note. He believes the "de-risked nature" of the known clinical data for gene therapy lead assets AT132 in X-Linked Myotubular Myopathy and AT342 in Crigler-Najjar Syndrome "goes underappreciated" at current share levels.
10/12/18
HCWC
10/12/18
NO CHANGE
Target $33
HCWC
Buy
Audentes Therapeutics price target lowered to $33 from $40 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Audentes Therapeutics to $33 after the company closed another secondary offering at $29 per share, which he notes represents a 17% discount to the January offering, which diluted shareholders by about 14%. The latest offering "leaves more than a sour taste in our mouths," Chattopadhyay tells investors in a research note. He believes Audentes had "no dire need to access the capital markets" and finds the timing and pricing of the offering "to be a little suspect." However, Chattopadhyay keeps a Buy rating on Audentes Therapeutics.
11/07/18
WBLR
11/07/18
DOWNGRADE
WBLR
Market Perform
Audentes downgraded to Market Perform from Outperform at William Blair
William Blair analyst Raju Prasad downgraded Audentes Therapeutics to Market Perform following the company's Q3 results. The analyst says increased competition in Pompe disease is giving him pause.
11/07/18
11/07/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Underperform from Sector Perform at RBC Capital with analyst Stephen Walker saying he points to the company's premium valuation ahead of what he expects to be a decline in 2019 production. 2. Zillow (Z, ZG) downgraded to Sell from Hold at Zelman and to Negative from Neutral at Susquehanna. 3. Mindbody (MB) downgraded to Neutral from Buy at UBS and Roth Capital as well as to Neutral from Overweight at JPMorgan. 4. Frontier Communications (FTR) downgraded to Sell from Neutral at UBS with analyst Batya Levi saying Frontier's free cash flow remains under pressure. 5. Audentes downgraded to Market Perform from Outperform at William Blair with analyst Raju Prasad saying increased competition in Pompe disease is giving him pause. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
QURE uniQure
$28.64

0.38 (1.34%)

11/26/18
HCWC
11/26/18
NO CHANGE
Target $60
HCWC
Buy
uniQure price target raised to $60 from $48 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for uniQure to $60 saying the company's pipeline augmentation that should be rewarded over the next 12 months. The recent R&D day disclosures of three new, "differentiated" gene therapy programs targeting Hemophilia A, Fabry, and SCA3 are likely to "further upend the HemB centric conversation during 2019 and beyond," Chattopadhyay tells investors in a research note. He keeps a Buy rating on shares of uniQure.
11/16/18
FBCO
11/16/18
UPGRADE
Target $44
FBCO
Neutral
Spark Therapeutics upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse analyst Martin Auster upgraded Spark Therapeutics (ONCE) to Neutral from Underperform but lowered his price target to $44 from $48. In a research note to investors, Auster says that with uniQure's (QURE) update validating AMT-061, its second generation hemophilia B gene therapy construct incorporating the Padua variant, and Freeline's initial data disclosed in ASH abstracts, he sees a more competitive landscape in hemophilia B gene therapy, and lowered his market share assumptions for SPK-9001 to reflect this new dynamic.However, Auster says Spark has been under significant pressure since providing an update on its hemophilia A, and believes most of the value for that program has already been discounted in the share price. Though there is limited visibility in the near-term, he sees optionality going forward within the Pompe program and/or a possible reemergence of the hem A platform ~mid-2019 from either an improved profile for SPK-8011 with prophy steroids or encouraging early data from Spark's second compound SPK-8016.
11/15/18
LEER
11/15/18
NO CHANGE
Target $76
LEER
Outperform
uniQure price target raised to $76 from $61 at Leerink
Leerink analyst Joseph Schwartz raised his price target for uniQure (QURE) to $76 from $61 as positive dose-confirmation data reaffirms his optimism for AMT-061 in hemophilia B. The analyst believes that uniQure's first attempt at using the Padua variant has shown early success and gives him incremental confidence heading into Phase 3 HOPE-B study, with patient dosing anticipated to commence in Q1 of 2019. Additionally, Schwartz argues that first data using the Padua variant looks "competitive" against Spark Therapeutics' (ONCE) SPK-9001. He reiterates an Outperform rating on uniQure's shares.
11/15/18
HCWC
11/15/18
NO CHANGE
Target $48
HCWC
Buy
uniQure's AMT-061 'living up to high expectations,' says H.C. Wainwright
uniQure (QURE) has provided investors with "a compelling glimpse at what the future hold for Hemophilia B patients" after issuing an update on its AMT-061 dose confirmation study, according to H.C. Wainwright analyst Debjit Chattopadhyay. The mean Factor IX activity at six weeks was 31%, which is on par with Spark Therapeutics' (ONCE) SPK-9001, said Chattopadhyay. The analyst, who thinks AMT-061 is "living up to high expectations" and views it being positioned as "not only the best-in-class one-and-done solution, but also, the first to market," keeps a Buy rating and $48 price target on uniQure shares.
RCKT Rocket Pharmaceuticals
$16.06

-0.29 (-1.77%)

11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
09/13/18
LTCO
09/13/18
INITIATION
Target $30
LTCO
Buy
Rocket Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Jonathan Hickman started Rocket Pharmaceuticals with a Buy rating and $30 price target. The analyst sees the company's "large" pipeline fueling its "rising" gene therapy portfolio.
11/27/18
LEER
11/27/18
INITIATION
Target $22
LEER
Outperform
Rocket Pharmaceuticals initiated with an Outperform at Leerink
Leerink analyst Mani Foroohar initiated Rocket Pharmaceuticals with an Outperform rating and a price target of $22.
07/10/18
WBLR
07/10/18
INITIATION
WBLR
Outperform
William Blair starts Rocket Pharmaceuticals with Outperform, $32 fair value
William Blair analyst Raju Prasad initiated coverage of Rocket Pharmaceuticals with an Outperform rating and $32 fair value estimate. The company is focused on developing first-in-class gene therapies for rare diseases, Prasad tells investors in a research note. The company's lead candidate, RP-L102, is an ex vivo lentiviral gene therapy being developed for the treatment of Fanconi anemia, with three additional ex vivo lentivirus programs in earlier development, the analyst adds. He believes leukocyte adhesion deficiency-I and pyruvate kinase deficiency could generate about $530M and $420M in revenue by 2027, respectively.
RGNX Regenxbio
$63.55

-0.89 (-1.38%)

11/27/18
LEER
11/27/18
INITIATION
Target $42
LEER
Underperform
Regenxbio initiated with an Underperform at Leerink
Leerink analyst Mani Foroohar initiated Regenxbio with an Underperform rating and a price target of $42.
08/13/18
LEHM
08/13/18
NO CHANGE
Target $83
LEHM
Overweight
Regenxbio price target raised to $83 from $48 at Barclays
Barclays analyst Gena Wang raised her price target for Regenxbio to $83 following the company's Q2 earnings report and update on clinical programs. The analyst sees RGX-314 data in wet age-related macular degeneration as encouraging and a "significant market opportunity" for the drug. While there was some setback for RGX-501 gene therapy in homozygous familial hypercholesterolemia, RGX-501 is not a major value driver for the stock, Wang tells investors in a research note. Her new price target reflects increased confidence in Regenxbio's wet-AMD program.
07/23/18
BOFA
07/23/18
DOWNGRADE
Target $80
BOFA
Neutral
Regenxbio downgraded to Neutral from Buy at BofA/Merrill
fBofA/Merrill analyst Ying Huang downgraded Regnxbio to Neutral from Buy citing fair valuation and raised its price target to $80 from $64 based on increased probabilities of success for its abeno-associated virus gene therapy programs.
CLLS Cellectis
$21.81

0.82 (3.91%)

04/24/18
JEFF
04/24/18
NO CHANGE
Target $27
JEFF
Buy
Epizyme shares will bounce back, says Jefferies
Jefferies analyst Michael Yee says that while the partial clinical hold is a bad headline, shares of Epizyme (EPZM) will bounce back like Cellectis (CLLS), Juno and others did when they modified the protocol and trial brochures to get back up and running. After speaking to management, Yee thinks Epizyme's partial clinical hold will be lifted in a few months. Until then, however, the shares could be in the penalty box, the analyst tells investors in a research note. He keeps a Buy rating on Epizyme with a $27 price target.
06/12/18
OPCO
06/12/18
NO CHANGE
Target $44
OPCO
Outperform
Cellectis price target raised to $44 from $40 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Cellectis to $44 from $40 after the company announced that the FDA approved its IND filing for UCART22 following a 30-day review period. The analyst reiterates an Outperform rating on the shares.
07/16/18
LEHM
07/16/18
INITIATION
Target $50
LEHM
Overweight
Cellectis initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Cellectis with an Overweight rating and $50 price target.
07/16/18
LEHM
07/16/18
INITIATION
Target $50
LEHM
Overweight
Barclays starts Cellectis with Overweight rating, $50 price target
Barclays analyst Gena Wang initiated coverage of Cellectis S.A. with an Overweight rating and $50 price target. Following "impressive data" and several approvals of personalized autologous CAR-T cell therapies in various blood cancers, universal off-the-shelf allogeneic CAR-T would be future therapeutic approach with improved timeline, costs and homogeneity, Wang tells investors in a research note. As a leader in allo-CART with its proprietary Talen gene editing technology, Cellectis is the only company with clinical experience, on two programs, the analyst adds. She believes the company has a "strong" pipeline of allogeneic CAR-Ts targeting advanced blood cancers.
NTLA Intellia Therapeutics
$17.09

1.105 (6.91%)

11/27/18
LEER
11/27/18
INITIATION
Target $23
LEER
Outperform
Intellia Therapeutics initiated with an Outperform at Leerink
Leerink analyst Mani Foroohar initiated Intellia Therapeutics with an Outperform rating and a price target of $23.
11/02/18
WEDB
11/02/18
DOWNGRADE
Target $20
WEDB
Neutral
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
Wedbush analyst David Nierengarten downgraded Intellia Therapeutics to Neutral from Outperform and lowered his price target to $20 from $36 as development delays push out initiation of the company's first clinical trial likely another six months to sometime in 2020. In a research note to investors, the analyst says he overall continues to see broad utility and value for the company's IP and CRISPR/Cas9 gene editing and lipid nanoparticle delivery capabilities, and is "encouraged" by recent LNP delivery enhancements and LNP-AAV hybrid activity in preclinical models; however, with a lack of meaningful catalysts over the next 12 months, Nierengarten suggests moving to the sidelines in the near term until there is more clarity around and approach the company's first IND filing.
11/02/18
WEDB
11/02/18
DOWNGRADE
WEDB
Neutral
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
CRSP Crispr Therapeutics
$37.70

1.34 (3.69%)

11/11/18
PIPR
11/11/18
NO CHANGE
Target $75
PIPR
Overweight
Piper Jaffray bullish on Crispr Therapeutics after SITC data
Piper Jaffray analyst Edward Tenthoff notes that Crispr Therapeutics presented a poster at SITC that showed the "impressive" capability of CRISPR/Cas9 to now introduce up to 7 edits to produce an allogeneic CART. The analyst believes the number of edits, unrivaled by other editing modalities, and strong efficiency with 50%-70% rates underscores the robust capabilities offered by CRISPR/Cas9 editing and could diversify the company's CAR-T pipeline in a competitive field. SITC data revealed quadruple-edited cells more potently inhibited tumor growth in vivo versus dual edits, he adds. Tenthoff points out that Crispr Therapeutics expects to initiate a Phase I study on CD19 CAR-T CTX110 in 1H19, with BCMA and CD70 CAR-Ts to follow. First-in-man CTX001 data next year could lead to accelerated approvals by 2021, he contended. The analyst reiterates an Overweight rating and $75 price target on the shares.
10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
10/10/18
10/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Take-Two (TTWO) initiated with an Outperform at Bernstein. 2. Shake Shack (SHAK) initiated with a Hold at Stifel. 3. Nu Skin (NUS) initiated with a Buy at DA Davidson. 4. Micron (MU) initiated with a Neutral at Piper Jaffray. 5. Crispr Therapeutics (CRSP) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/18
WELS
10/10/18
INITIATION
Target $65
WELS
Outperform
Crispr Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Crispr Therapeutics with an Outperform rating and $65 price target. The analyst cited the company's "highly leverageable" gene editing platform, "substantially de-risked" lead program in ex-vivo gene editing for beta thalassemia and sickle cell disease, a broad pipeline of both ex vivo and in vivo gene-editing opportunities, and strong collaborations balancing wholly owned programs to optimize future value creation.

TODAY'S FREE FLY STORIES

MS

Morgan Stanley

$42.16

-0.24 (-0.57%)

07:21
01/24/19
01/24
07:21
01/24/19
07:21
Hot Stocks
Morgan Stanley CEO: Shutdown could have 'extremely damaging' impact »

Gorman is speaking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAH

Platform Specialty Products

$10.90

-0.15 (-1.36%)

07:19
01/24/19
01/24
07:19
01/24/19
07:19
Hot Stocks
Platform Specialty Products receives regulatory approval for Arysta sale »

Platform Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MB

Mindbody

$36.41

-0.19 (-0.52%)

07:19
01/24/19
01/24
07:19
01/24/19
07:19
Downgrade
Mindbody rating change  »

JMP downgrades Mindbody…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$205.77

2.77 (1.36%)

07:18
01/24/19
01/24
07:18
01/24/19
07:18
Upgrade
Palo Alto Networks rating change  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Feb

PG

Procter & Gamble

$94.87

4.37 (4.83%)

07:18
01/24/19
01/24
07:18
01/24/19
07:18
Recommendations
Procter & Gamble analyst commentary  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 03

    Mar

NMCI

Navios Maritime Containers

$3.03

(0.00%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Hot Stocks
Navios Maritime Containers exercises option to acquire containership for $52.5M »

Navios Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAPR

Capricor Therapeutics

$0.58

-0.0751 (-11.46%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Hot Stocks
Capricor Therapeutics announces HOPE-Duchenne trial results published »

Neurology, an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$95.49

-1.05 (-1.09%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

NESRF

Northern Star Resources

$0.00

(0.00%)

07:16
01/24/19
01/24
07:16
01/24/19
07:16
Downgrade
Northern Star Resources rating change  »

Northern Star Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
01/24/19
01/24
07:15
01/24/19
07:15
General news
FX Update: The dollar has posted advances »

FX Update: The dollar has…

EEX

Emerald Expositions Events

, RELX

RELX

$21.78

-0.03 (-0.14%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Recommendations
Emerald Expositions Events, RELX analyst commentary  »

Emerald Expositions a…

EEX

Emerald Expositions Events

RELX

RELX

$21.78

-0.03 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$94.87

4.37 (4.83%)

, EL

Estee Lauder

$126.94

1.19 (0.95%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Recommendations
Procter & Gamble, Estee Lauder, Church & Dwight analyst commentary  »

P&G report has…

PG

Procter & Gamble

$94.87

4.37 (4.83%)

EL

Estee Lauder

$126.94

1.19 (0.95%)

CHD

Church & Dwight

$65.45

-0.7 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 05

    Feb

  • 18

    Feb

  • 03

    Mar

  • 28

    May

USAP

Universal Stainless & Alloy

$14.62

-0.515 (-3.40%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Hot Stocks
Universal Stainless & Alloy increases low alloy VAR bar base price 5%-10% »

Universal Stainless &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

07:12
01/24/19
01/24
07:12
01/24/19
07:12
Recommendations
Xilinx analyst commentary  »

Xilinx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CNOB

ConnectOne Bancorp

$20.08

-0.19 (-0.94%)

07:11
01/24/19
01/24
07:11
01/24/19
07:11
Earnings
ConnectOne Bancorp reports Q4 adj. EPS 59c, consensus 55c »

As of December 31, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AEP

American Electric

$77.00

0.65 (0.85%)

07:11
01/24/19
01/24
07:11
01/24/19
07:11
Earnings
Breaking Earnings news story on American Electric »

American Electric backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AEP

American Electric

$77.00

0.65 (0.85%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Earnings
American Electric reports Q4 EPS 74c, consensus 71c »

Reports Q4 revenue $3.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

LVS

Las Vegas Sands

$57.25

0.26 (0.46%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Recommendations
Las Vegas Sands analyst commentary  »

Las Vegas Sands price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

CNCE

Concert Pharmaceuticals

$14.02

-0.26 (-1.82%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Hot Stocks
Concert Pharmaceuticals initiates Phase 1 single-ascending dose trial of CTP-692 »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 30

    Jan

  • 12

    Feb

  • 13

    Feb

MDR

McDermott

$8.49

0.01 (0.12%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Hot Stocks
McDermott announces ethylene furnace award in Indonesia »

McDermott announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

BWB

Bridgewater Bancshares

$10.41

-0.17 (-1.61%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Earnings
Bridgewater Bancshares reports Q4 EPS 25c, two est. 23c »

The fourth quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDC

China Lending Corp.

$1.11

-0.005 (-0.45%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Hot Stocks
China Lending Corp. acquires minority interest in financial service company »

China Lending Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

RCI

Rogers Communications

$54.51

-0.12 (-0.22%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Earnings
Rogers Communications sees FY19 revenue up 3%-5% »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

LIVX

LiveXLive Media

$6.25

-0.05 (-0.79%)

07:08
01/24/19
01/24
07:08
01/24/19
07:08
Recommendations
LiveXLive Media analyst commentary  »

LiveXLive Media price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRIS

Curis

$1.06

-0.045 (-4.09%)

07:08
01/24/19
01/24
07:08
01/24/19
07:08
Hot Stocks
Curis says first mesothelioma patient dosed in CA-170 study »

Curis announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.